IDEAYA Biosciences Inc

자세한 내용은 IDEAYA Biosciences Inc 회사

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

회사 정보

종목 코드 IDYA

회사 이름IDEAYA Biosciences Inc

상장일May 23, 2019

설립일2015

CEOMr. Yujiro S. Hata

직원 수131

유형Ordinary Share

회계 연도 종료May 23

주소7000 Shoreline Ct, Suite 350

도시SOUTH SAN FRANCISCO

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호94080

전화16504436209

웹사이트https://www.ideayabio.com/

종목 코드 IDYA

상장일May 23, 2019

설립일2015

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Joshua Bleharski, Ph.D.

Chief Financial Officer

--

Dr. Catherine J. Mackey, Ph.D.

Independent Director

--

Dr. M. Garret Hampton, Ph.D.

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

Dr. Darrin Beaupre, M.D., Ph.D.

Chief Medical Officer

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

Independent Director

--

Mr. Andres Ruiz Briseno, CPA

Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations

--

Dr. Michael A. White, Ph.D.

Chief Scientific Officer

--

Ms. Wendy L. Yarno

Independent Director

--

Mr. Yujiro S. Hata

President, Chief Executive Officer, Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Joshua Bleharski, Ph.D.

Chief Financial Officer

--

Dr. Catherine J. Mackey, Ph.D.

Independent Director

--

Dr. M. Garret Hampton, Ph.D.

Independent Director

--

Dr. Terry J. Rosen, Ph.D.

Independent Chairman of the Board

--

Dr. Darrin Beaupre, M.D., Ph.D.

Chief Medical Officer

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

Independent Director

--

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2024

FY2024Q4

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

사업별USD

이름

수익

비율

WRN

7.00M

0.00%

MAT2A

0.00

0.00%

Pol Theta

0.00

0.00%

지역별USD

이름

수익

비율

United States

7.00M

100.00%

사업별

지역별

사업별USD

이름

수익

비율

WRN

7.00M

0.00%

MAT2A

0.00

0.00%

Pol Theta

0.00

0.00%

주식 보유 통계

마지막 업데이트: Tue, Jul 1

주주

주주 유형

주주

비율

Fidelity Management & Research Company LLC

14.99%

BlackRock Institutional Trust Company, N.A.

8.17%

Janus Henderson Investors

7.31%

The Vanguard Group, Inc.

5.80%

Federated Hermes Global Investment Management Corp.

5.44%

Other

58.29%

주주

비율

Fidelity Management & Research Company LLC

14.99%

BlackRock Institutional Trust Company, N.A.

8.17%

Janus Henderson Investors

7.31%

The Vanguard Group, Inc.

5.80%

Federated Hermes Global Investment Management Corp.

5.44%

Other

58.29%

주주 유형

주주

비율

Investment Advisor

45.54%

Investment Advisor/Hedge Fund

33.49%

Hedge Fund

21.64%

Venture Capital

8.56%

Research Firm

4.37%

Individual Investor

0.91%

Pension Fund

0.77%

Sovereign Wealth Fund

0.59%

Bank and Trust

0.34%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

444

101.86M

116.30%

-6.31M

2025Q1

454

97.81M

111.68%

-11.15M

2024Q4

442

95.26M

108.96%

-7.87M

2024Q3

426

95.20M

112.79%

+2.56M

2024Q2

409

85.26M

112.59%

-3.91M

2024Q1

388

81.45M

108.91%

-1.44M

2023Q4

351

68.31M

105.94%

-512.62K

2023Q3

331

61.92M

105.66%

-3.64M

2023Q2

313

59.35M

103.37%

+5.88M

2023Q1

290

47.36M

97.90%

-6.95M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Fidelity Management & Research Company LLC

13.13M

14.99%

+167.11K

+1.29%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

7.15M

8.17%

+286.75K

+4.18%

Mar 31, 2025

Janus Henderson Investors

6.40M

7.31%

+544.14K

+9.29%

Mar 31, 2025

The Vanguard Group, Inc.

5.08M

5.8%

+14.54K

+0.29%

Mar 31, 2025

Federated Hermes Global Investment Management Corp.

4.77M

5.44%

-295.60K

-5.84%

Mar 31, 2025

Point72 Asset Management, L.P.

4.41M

5.04%

+4.27M

+3048.93%

Jun 06, 2025

Logos Global Management LP

3.50M

4%

+500.00K

+16.67%

Mar 31, 2025

State Street Global Advisors (US)

3.45M

3.93%

+125.33K

+3.77%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.39M

3.87%

-395.42K

-10.45%

Mar 31, 2025

Deerfield Management Company, L.P.

3.27M

3.73%

+531.55K

+19.43%

Mar 31, 2025

25.020USD

IDEAYA Biosciences Inc

25.020

개요

회사

금융